STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Dianthus Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. Schedule 13G/A reports that Point72-related entities and Steven A. Cohen collectively have shared voting and dispositive power over 1,445,825 shares of Dianthus common stock, representing 4.5% of the class as of the close of business on June 30, 2025. The filing states the shares are held by an investment fund managed by Point72 Asset Management; Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management and Mr. Cohen controls both entities. Each reporting person reports 0 sole voting and 0 sole dispositive power, with all reported power listed as shared. The statement clarifies the filing should not be construed as admission of beneficial ownership for purposes of Section 13.

Positive
  • Transparent disclosure of holdings: 1,445,825 shares reported with specific shared voting and dispositive power
  • Clear chain of control identified: Point72 Asset Management manages the fund, Point72 Capital Advisors is general partner, and Steven A. Cohen controls the entities
  • Position below 5% threshold (4.5%), consistent with passive reporting under Schedule 13G/A
Negative
  • None.

Insights

TL;DR: Point72 reports a 4.5% shared stake in Dianthus, a non-controlling position below the 5% threshold.

Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen disclose shared voting and dispositive power over 1,445,825 shares as of June 30, 2025. The filing shows no sole voting or dispositive power and explicitly notes the position is not intended to influence control of the issuer. Because the stake is under 5%, this is a routine Section 13G disclosure reflecting passive or qualifying investor status rather than an active acquisition or control intent. Investors should view this as a transparency filing rather than a material change to corporate control.

TL;DR: Disclosure is complete and consistent with passive ownership reporting; ownership structure shows common control through Point72 entities.

The document identifies the reporting chain: Point72 Asset Management manages the fund owning the shares, Point72 Capital Advisors is the general partner, and Steven A. Cohen controls those entities. The certification clarifies the securities were not acquired to change control. All signatures are executed by an authorized person. From a governance perspective, the filing documents influence via shared powers but does not indicate an active control campaign.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Point72 Capital Advisors, Inc
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025

FAQ

How many Dianthus (DNTH) shares do Point72 and Steven A. Cohen report?

They report shared voting and dispositive power over 1,445,825 shares, equal to 4.5% of the class as of June 30, 2025.

Does the Schedule 13G/A indicate Point72 seeks control of Dianthus (DNTH)?

No. The filing includes a certification stating the securities were not acquired to change or influence control and were not acquired in connection with such a transaction.

What voting and dispositive powers are reported by the filers?

Each reporting person reports 0 sole voting and 0 sole dispositive power, and 1,445,825 shared voting and 1,445,825 shared dispositive power.

Which Point72 entities are named in the filing for DNTH?

The filing names Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. and lists Steven A. Cohen as a reporting person.

As of what date are the reported holdings for DNTH effective?

The holdings are reported as of the close of business on June 30, 2025.
Dianthus Therapeutics Inc

NASDAQ:DNTH

DNTH Rankings

DNTH Latest News

DNTH Latest SEC Filings

DNTH Stock Data

1.77B
40.22M
7.86%
123%
17.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK